Summary
Nafcillin is a semisynthetic penicillin that is generally well tolerated with few side effects. Hepatic complications are rare but have a potential for serious liver dysfunction. This unusual complication causes a predominantly cholestatic injury, which can persist for prolonged periods even after discontinuing the medication. The pathophysiology may include direct cytotoxicity or an immune-mediate hypersensitivity. Treatment is generally supportive, except for severely symptomatic patients who may require steroids. We report a case of nafcillin-associated hepatotoxicity and review the literature of this disorder.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bruckstein AH, Attia AA: Oxacillin Hepatitis. Am J Med 64:519–522, 1978
Dismukes WE: Oxacillin-induced hepatic dysfunction. JAMA 266:861–863, 1973
Klein I, Lillel T: Oxacillin-associated hepatitis. Am J Gastroenterol 65:546–547, 1976
Olans RN, Weiner LB: Reversible oxacillin hepatotoxicity. J Pediatr 89:835–838, 1976
Onorato IM, Axelrod JL: Hepatitis from intravenous high-dose oxacillin therapy. Ann Intern Med 89:497–500, 1978
Pollock AA, Berger SA, Simberkoff MS, Rahal JJ: Hepatitis associated with high-dose oxacillin therapy. Arch Intern Med 138:915–917, 1978
Taylor C, Corrigan K, Steen S, Craig C: Oxacillin and hepatitis. Ann Intern Med 90:857–858, 1979
Ten Pas A, Quinn EI: Cholestatic hepatitis following the administration of sodium oxacillin. JAMA 191:138–139, 1965
Bass NM, Ockner RK: Drug-induced liver disease.In Hepatology, D Zakim TD Boyer (eds). Philadelphia, WB Saunders, 1990, pp 754–791
Miller WI, Souney PF, Chang JT: Hepatic dysfunction following nafeillin and cephalothin therapy in a patient with a history of oxacillin hepatitis. Clin Pharmacol 2:465–468, 1983
Bengtsson F, Floren CH, Hagerstrand I, Soderstrom C, Aberg T: Flucloxacillin-induced cholestatic liver damage. Scand J Infect Dis 17:125–128, 1985
Enat R, Pollack S, Ben-Arich Y, Livini E, Barzilai D: Cholestatic jaundice caused by cloxacillin: macrophage inhibitor factor test in preventing rechallenge with hepatotoxic drugs. BMJ 260:982–983, 1980
Goldstein LI, Ishak KG: Hepatic injury associated with penicillin therapy. Arch Pathol 98:114–117, 1974
Kleinman MS, Presberg JE: Cholestatic hepatitis after dicloxacillin-sodium therapy. J Clin Gastroenterol 8:77–78, 1986
Konikoff F, Alcalay J, Halevy J: Cloxacillin-induced cholestatic jaundice. Am J Gastroenterol 81:1082–1083, 1986
Lobatto S, Dijkmans B, Mattie H, Van Hooff JP: Flucloxacillin-associated liver damage. Neth J Med 24:47–48, 1982
Tauris P, Jorgensen JF, Petersen CM, Albertsen K: Prolonged severe cholestasis induced by oxacillin derivatives. Acta Med Scand 217:567–569, 1985
Lestico MR, Vick KE, Hetsko CM: Hepatic and renal dysfunction following nafcillin administration. Ann Pharmacother 26:985–990, 1992
Mazuryk H, Kastenberg D, Rubin R, Munoz S: Cholestatic hepatitis associated with the use of nafcillin. Am J Gastroenterol 88:1960–1962, 1993
Ryan J, Dudley FJ: Cholestasis with ticarcillin-potassium clavulanate (Timentin). Med J Aust 156:291, 1992
Schwartz MS, Frank MS, Yanoff A, Morecki R: Atenololassociated cholestasis. Am J Gastroenterol 84:1084–1086, 1989
Wong FS, Ryan J, Dabkowski P, Dudley FJ, Sewell RB, Smallwood RA: Augmentin-induced jaundice. Med J Aust 154:698–701, 1991
Eng C, Javitt NB: Effect of nafcillin on hepatic excretory function. Biochem Pharmacol 32:3649–3651, 1983
Aderka D, Livini E, Salamon F, Weinberger A, Pinkhas J: Use of macrophage inhibition factor and mast-cell degranulation tests for diagnosis of cloxacillin induced cholestasis. Am J Gastroenterol 81:1084–1086, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Presti, M.E., Janney, C.G. & Neuschwander-Tetri, B.A. Nafcillin-associated hepatotoxicity. Digest Dis Sci 41, 180–184 (1996). https://doi.org/10.1007/BF02208602
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02208602